Lakefront Biotherapeutics (LKFT) Non Operating Income (2016 - 2026)
Lakefront Biotherapeutics (LKFT) reported Non Operating Income of -$160392.2 for Q1 2026, up 80.45% year-over-year from -$88884.0 in Q1 2025, and up 79.37% quarter-over-quarter from -$777421.6 in Q3 2025.
Lakefront Biotherapeutics (LKFT) Non Operating Income (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 11 years of Non Operating Income data on file, last reported at -$160392.2 in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$160392.2, up 80.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 179.39% YoY), and the FY2024 annual result was $4.5 million, up 734.27% from the prior year.
- Non Operating Income advanced to -$160392.2 in Q1 2026 per LKFT's latest filing, from -$777421.6 in the prior quarter.
- Over five years, Non Operating Income peaked at $5.4 million in Q4 2022 and troughed at -$81.4 million in Q3 2022.
- A 5-year average of -$5.3 million and a median of -$661064.5 in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income surged 168.08% in 2024, then plunged 353.66% in 2025.
- A 5-year view of Non Operating Income shows it stood at $5.4 million in 2022, then sank by 68.89% to $1.7 million in 2023, then surged by 168.08% to $4.5 million in 2024, then slumped by 117.32% to -$777421.6 in 2025, then surged by 79.37% to -$160392.2 in 2026.
- Business Quant data shows LKFT's Non Operating Income at -$160392.2 in Q1 2026, -$777421.6 in Q3 2025, and -$661064.5 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 9.35 Mn |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -160,392.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -160,392.15 |
| Sep 30, 2025 | -777,421.64 |
| Jun 30, 2025 | -661,064.46 |
| Mar 31, 2025 | -820,469.86 |
| Dec 31, 2024 | 4.49 Mn |
| Sep 30, 2024 | -880,772.04 |
| Jun 30, 2024 | 260,606.79 |
| Mar 31, 2024 | -275,935.89 |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | -1.80 Mn |
| Mar 31, 2023 | -905,900.50 |
| Dec 31, 2022 | 5.38 Mn |
| Sep 30, 2022 | -81.44 Mn |
| Mar 31, 2022 | -4.72 Mn |
| Jun 30, 2021 | -9.80 Mn |
| Mar 31, 2021 | -13.68 Mn |
| Jun 30, 2020 | -2.62 Mn |
| Mar 31, 2020 | -27.46 Mn |
| Sep 30, 2019 | -42.99 Mn |